新型冠状病毒感染与CAR-T耐药双重挑战下的格菲妥单抗治疗:难治性弥漫大B细胞淋巴瘤1例报告

doi:10.3969/j.issn.1674-5671.2024.05.09

Abstract

Abstract: The data of a patient with refractory diffuse large B⁃cell lymphoma, who was failed to chimeric antigen receptor T (CAR⁃T) cell therapy, are analyzed in this report. The patient achieved complete remission after receiving glofitamab with combination of coronavirus disease 2019 (COVID⁃19), and no other serious adverse events such as aggravation of COVID⁃19 were observed. Meanwhile, the efficacy of Glofitamab in the treatment of refractory diffuse large B⁃cell lymphoma is reviewed, and the safety of bispecific antibodies in patients with lymphoma complicated with COVID⁃19 is evaluated.

Key words: Diffuse large B cell lymphoma, Chimeric antigen receptor T cell, Glofitamab, Bispecific antibody, COVID?19, Lymphoma

CLC Number:

R733.4

BI Jianghan, ZHANG Yan, WANG Wei . Glofitamab therapy under the dual challenge of novel coronavirus infection and CAR-T resistance: a case report of refractory diffuse large B-cell lymphoma[J].Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 566-570.

[1]	ZENG Lijie, WANG Liang, YANG Lei . Clinical features and treatment efficacy analysis of central nervous system involvement in extranodal nasal-type natural killer/T-cell lymphoma [J]. Chinese Journal of Oncology Prevention and Treatment, 2025, 17(1): 81-87.
[2]	LI Siyuan, ZHANG Yan, ZHANG Lu. Application and challenge of CAR-T cell therapy in autoimmune diseases [J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 516-524.
[3]	LI Mengjiao, CEN Yali, DOU Baitao, SHU Rou, LI Yanling, QIU Ling, REN Shihui, YAO Hao, FAN Fangyi. Advances in the application of molecular targeted drugs combined with CAR-T cell therapy in lymphoma [J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 532-539.
[4]	LYU Liwei, CONG Jia, WU Yiping, WANG Liang . BCMA CAR-T cell therapy for relapsed/refractory plasmablastic lymphoma: case report and clinical implication [J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 562-565.
[5]	HE Ying, LI Mengjiao, CEN Yali, DOU Baitao, SHU Rou, LI Yanling, YAO Hao, FAN Fangyi. CD19 CAR T-cell therapy: a case of refractory primary central nervous system diffuse large B-cell lymphoma [J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 571-576.
[6]	YANG Lei, ZENG Lijie, TAO Jianhua, YAO Na, CONG Jia, YANG Jing, WANG Henan, WEI Liqiang, WANG Liang. Clinical analysis of extranodal NK/T-cell lymphoma,nasal type,manifesting with primary ocular lesions [J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(3): 321-326.
[7]	ZHANG Kaimin, HUANG Yujie, DUAN Ying, GUO Baoping, KE Qing, LIAO Chengcheng, CEN Hong . Anti⁃tumor effect of PI3K inhibitor Linperlisib on diffuse large B⁃cell lymphoma in vitro [J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(1): 56-61.
[8]	GUO Jia, WANG Chengji, LIANG Yuanzheng, WANG Liang. Clinical analysis of rituximab-induced interstitial lung disease in newly treated patients with diffuse large B-cell lymphoma: A retrospective study of single-center [J]. Chinese Journal of Oncology Prevention and Treatment, 2023, 15(4): 391-397.
[9]	WEI Chong, ZHAO Danqing, ZHANG Yan, WANG Wei, ZHANG Wei, ZHOU Daobin . Chidamide combined with azacitidine in treating relapsed/refractory angioimmunoblastic T⁃cell lymphoma: a prospective clinical study [J]. Chinese Journal of Oncology Prevention and Treatment, 2023, 15(1): 51-55.
[10]	ZHANG Xuefang, DIAO Xiaoli, WANG Shuzhen. Primary ovarian diffuse large B⁃cell lymphoma: 4 cases report and literature review [J]. Chinese Journal of Oncology Prevention and Treatment, 2022, 14(6): 653-658.
[11]	FU Ruiying, LIU Xindi, LIANG Yuanzheng, LIU Xuelin, WANG Liang. The role of lncRNA BCYRN1 in activation of glycolysis in extranodal NK/T⁃cell lymphoma and its mechanism [J]. Chinese Journal of Oncology Prevention and Treatment, 2022, 14(4): 370-377.
[12]	WANG Jia, ZHAI Zhimin, GE Jian, WANG Xingbing, DONG Yi. Effects of extramedullary diseases and regulatory T cells on the treatment efficacy of chimeric antigen receptor T cells in multiple myeloma [J]. Chinese Journal of Oncology Prevention and Treatment, 2022, 14(4): 400-406.
[13]	LIU Fuhong, XUE Song, ZHANG Yongping, HUANG Wenqiu, WANG Jingbo. Allogeneic hematopoietic stem cell transplantation for T cell acute lymphoblastic leukemia and lymphoma: a clinical report of 50 cases [J]. Chinese Journal of Oncology Prevention and Treatment, 2022, 14(1): 81-86.
[14]	LUO Yanzhen, ZHOU Da, CHEN Sijing, LIAO Chengcheng, WANG Mingyue, TAN Xiaohong, KE Qing, CEN Hong. Relationship between tumor⁃associated macrophages and prognosis of diffuse large B⁃cell lymphoma [J]. Chinese Journal of Oncology Prevention and Treatment, 2022, 14(1): 87-93.
[15]	LIU Xuanyong, GUO Zhi, XIE Jing, CHEN Lina, WANG Yueqiao, ZHANG Yi⁃huizhi, CHEN Xiao, LI Xumian, WEI Liya, . Efficacy of PD⁃1 inhibitors in the maintenance treatment for diffuse large B⁃cell lymphoma: A single⁃center retrospective case⁃control study [J]. Chinese Journal of Oncology Prevention and Treatment, 2021, 13(4): 359-364.

Glofitamab therapy under the dual challenge of novel coronavirus infection and CAR-T resistance: a case report of refractory diffuse large B-cell lymphoma

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 0